Investigators evaluated patient-reported outcomes and tolerability of capivasertib plus abiterone in PTEN-deficient metastatic hormone-sensitive prostate cancer.
"We are very pleased to welcome Bryan to Zenith's board of directors," said Donald McCaffrey, Chairman and CEO. "Bryan has an excellent reputation for prudent advice and creative insights, and we look ...
Zenith Capital Corp. ("Zenith" or the "Company") today announces the appointment of Mr. Bryan R. Ede, J.D. as a member of the Company's Board of ...
The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032, registering a CAGR of 7.47% during ...
Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...
Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
March is the awareness month for colorectal cancer and multiple myeloma. If you’re interested in speaking to experts, contact media@fredhutch.org to schedule interviews. Scientists develop ...
Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, has sponsored PanCAN PurpleStride for 10+ years, this year for PurpleStride Miami and Broward-Palm Beach ...
BRASILIA-(MaraviPost)-Brazilian giants Flamengo have sent shockwaves across South American football after dismissing head coach Filipe Luís just hours after the team secured a resounding 8–0 victory ...
Abstracts presented at ASCO GU examined whether the radioligand therapy impacts or is affected by ARPIs or chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results